What is the significance of CSF oligoclonal bands, IgG index, serum aquaporin‑4 antibodies, serum myelin‑associated glycoprotein antibodies, vitamin B12 and folate levels, and autoimmune serologies (ANA, anti‑SSA/SSB, rheumatoid factor) in diagnosing multiple sclerosis versus other demyelinating diseases?

Laboratory Significance in Diagnosing MS versus Other Demyelinating Diseases

CSF oligoclonal bands (OCBs) are the single most important laboratory test for distinguishing MS from other demyelinating diseases, being positive in up to 98% of MS patients but only 12-13% of MOG-EM patients, making their absence a strong indicator to consider alternative diagnoses like MOGAD or NMOSD.

CSF Oligoclonal Bands and IgG Index

CSF-restricted oligoclonal bands represent the gold standard for demonstrating intrathecal IgG synthesis and are now incorporated into the 2024 McDonald criteria for MS diagnosis 1, 2. The diagnostic significance is striking:

• MS: Present in 90-98% of patients in Central/Northern Europe (lower rates of 40-80% in Asian populations) 1
• MOG-EM: Only 12-13% positive 1
• NMOSD-AQP4: Rarely positive 3, 4

Critical interpretation points:

• Absence of OCBs should prompt testing for MOG-IgG and AQP4-IgG antibodies, as many MOG-EM patients previously misdiagnosed with MS were atypical in lacking OCBs 1
• Positive OCBs do NOT exclude MOG-EM entirely, but make it less likely 1
• When OCBs are present in NMOSD, they associate with higher CSF cell counts, more frequent relapses, and concomitant autoimmune conditions 4

The IgG index (elevated >0.72) is less sensitive than OCBs, detecting intrathecal synthesis in only 45% of MS patients versus 100% with isoelectric focusing 5. Use it as adjunctive evidence when OCBs are equivocal, but never rely on it alone.

Serum Aquaporin-4 Antibodies

AQP4-IgG testing is mandatory to distinguish NMOSD from MS, as these represent fundamentally different diseases requiring different treatments 1, 6.

Key diagnostic features:

• Positive AQP4-IgG essentially excludes MS and confirms NMOSD
• Almost all MOG-IgG positive patients lack AQP4-IgG 1
• In pediatric cohorts with suspected MS, AQP4-IgG positivity is extremely rare (0% in one 493-patient cohort) 7
• Use cell-based assays for optimal sensitivity and specificity

When to test: Any patient with longitudinally extensive transverse myelitis (≥3 vertebral segments), bilateral optic neuritis, area postrema syndrome, or atypical MS features 6.

Serum MOG Antibodies

MOG-IgG testing using cell-based assays with full-length conformationally intact MOG is essential for identifying MOG-EM, a distinct entity from MS that requires different treatment approaches 1.

Diagnostic patterns that mandate MOG-IgG testing 1:

• Bilateral or recurrent optic neuritis
• Longitudinally extensive optic nerve lesions (>50% length)
• ADEM-like presentations
• Absence of Dawson's fingers or periventricular ovoid lesions on MRI
• Absence of CSF oligoclonal bands
• Neutrophilic CSF pleocytosis (median 22% neutrophils)
• CSF white cell count >100 cells/μL
• Symptom recurrence after steroid tapering

Critical distinctions from MS 1, 7:

• MOG-EM patients are typically younger at onset (mean 8.2 vs 14.7 years in pediatric cohorts)
• Only 12-13% have OCBs versus 90-98% in MS
• 33% may meet McDonald criteria at some point, leading to misdiagnosis
• MS treatments may be ineffective or harmful in MOG-EM

Important caveats 1:

• MOG-IgG restricted to CSF only (without serum positivity) is rare but when present, paradoxically associates with MS rather than MOG-EM, particularly in older children with OCBs 8
• Borderline positive results require confirmation with alternative assays
• Double-positive AQP4/MOG results are extremely rare and should prompt retesting

Vitamin B12 and Folate

Check B12 and folate levels in all suspected demyelinating cases to exclude subacute combined degeneration of the spinal cord, which can mimic progressive myelopathy 1. This is a "red flag" diagnosis that must be excluded before attributing symptoms to MS or other inflammatory demyelination.

Autoimmune Serologies (ANA, Anti-SSA/SSB, Rheumatoid Factor)

Screen for systemic autoimmune diseases as they frequently coexist with demyelinating disorders, particularly in certain patterns:

• In MOG-EM: Concomitant connective tissue disease occurs in a subset of patients 4
• In NMOSD: Strong association with other autoimmune conditions; OCB-positive NMOSD patients have higher rates of concomitant CTD (33.3% vs 8.6%) and other autoimmune antibodies (60% vs 28.9%) 4
• In MS: Less commonly associated with systemic autoimmunity

The presence of multiple autoimmune antibodies should raise suspicion for NMOSD over MS, particularly when combined with OCB negativity.

Myelin-Associated Glycoprotein Antibodies

MAG antibodies are not relevant for MS diagnosis and instead indicate a peripheral demyelinating neuropathy (anti-MAG neuropathy). Their presence should prompt reconsideration of the diagnosis, as MOG is not expressed in the peripheral nervous system and combined central-peripheral demyelination is a "red flag" against MOG-EM 1.

Algorithmic Approach to Laboratory Testing

Step 1: Obtain CSF for OCBs and basic studies (cell count with differential, protein, IgG index)

Step 2: Interpret OCB results:

• Positive OCBs (≥2 CSF-specific bands): Strongly supports MS; proceed with MRI correlation
• Negative OCBs: Immediately test serum for AQP4-IgG and MOG-IgG using cell-based assays

Step 3: If OCBs negative and clinical/radiological features atypical for MS:

• High CSF WBC (>100 cells/μL) or neutrophil predominance → test MOG-IgG
• Longitudinally extensive lesions → test both AQP4-IgG and MOG-IgG
• Younger age, bilateral ON, or ADEM phenotype → test MOG-IgG

Step 4: Screen for mimics:

• B12 and folate (always)
• ANA, anti-SSA/SSB, RF (particularly if OCBs negative or multiple system involvement)

Step 5: If MOG-IgG or AQP4-IgG positive, confirm diagnosis is not MS and adjust treatment accordingly, as MS therapies may worsen these conditions 1.